Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Amortizatization of Intangibles (2023 - 2025)

Historic Amortizatization of Intangibles for Krystal Biotech (KRYS) over the last 3 years, with Q4 2025 value amounting to $200000.0.

  • Krystal Biotech's Amortizatization of Intangibles rose 471.2% to $200000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $827000.0, marking a year-over-year increase of 1070.95%. This contributed to the annual value of $827000.0 for FY2025, which is 1070.95% up from last year.
  • Latest data reveals that Krystal Biotech reported Amortizatization of Intangibles of $200000.0 as of Q4 2025, which was up 471.2% from $209000.0 recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Amortizatization of Intangibles registered a high of $233000.0 during Q4 2023, and its lowest value of $182000.0 during Q1 2024.
  • In the last 3 years, Krystal Biotech's Amortizatization of Intangibles had a median value of $204500.0 in 2025 and averaged $206500.0.
  • Per our database at Business Quant, Krystal Biotech's Amortizatization of Intangibles plummeted by 1826.09% in 2024 and then soared by 2307.69% in 2025.
  • Krystal Biotech's Amortizatization of Intangibles (Quarter) stood at $233000.0 in 2023, then decreased by 18.03% to $191000.0 in 2024, then rose by 4.71% to $200000.0 in 2025.
  • Its last three reported values are $200000.0 in Q4 2025, $209000.0 for Q3 2025, and $194000.0 during Q2 2025.